IN THE CLAIMS

Claims 1-75 (Canceled).

76. (Allowed) A method of treating a host infected with a virus of the Flaviviridae, Rhabdoviridae or Paramyxoviridae family, which method comprises administering to the host an inhibitor of dihydroorotate dehydrogenase, wherein the inhibitor is a compound of the formula (I):



(I)

wherein

each A is independently selected from the group consisting of hydrogen, hydroxy, halogen, perhaloalkoxy, amino C_1-C_8 alkyl, NO_2, CN, SO_2CH_3, C_1-C_8 alkyl, C_1-C_8 alkoxy, C_3-C_7 cycloalkyl, C_3-C_7 cycloalkenyl, aryl, aryloxy, C_1-C_6 perhaloalkyl and Y; or two adjacent groups A on ring b form, together with the phenyl ring to which they are attached, a naphthalene ring system;

R is cyclohexyl, phenoxy or benzoxy, or a phenyl ring which is unsubstituted or substituted by a group A as defined above; or

R and an adjacent group A on ring b form, together with the phenyl ring to which they are attached, a naphthalene or phenanthrene ring system;

Y is selected from the group consisting of COOM, CONHR', SO_3M and hydrogen;

M is selected from the group consisting of H, Li, Na, K and O.5 Ca;

R' is C_1-C_{10} alkyl;

n is 1 or 2; and

T is =N or =C(Z) wherein either:

(i) Z is selected from the group consisting of hydrogen, NH_2., OH, C_1-C_8 alkyl, C_3-C_7 cycloalkyl, aryl and C_1-C_6 perhaloalkyl, or

(ii) Z is a bridging moiety selected from the group consisting of -V-W- (wherein V is CH_2 or S and W is CH_2, O, S or NH) and -$(CH_2)_2$ -C(=Z)- wherein Z is O or H_2, the said bridging moiety being attached to the ortho position of ring b of the adjacent biphenyl group, thereby completing a ring.

77. (Allowed) A method according to claim 76, wherein the inhibitor is a compound of formula (Ia):



(Ia)

wherein:

each A is independently selected from the group consisting of hydrogen, halogen, amino C_1-C_8 alkyl, NO_2, CN, SO_2CH_3, C_1-C_8 alkyl, C_3-C_7 cycloalkyl, aryl, C_1-C_6

perhaloalkyl and Y;

Y is selected from the group consisting of COOM, CONHR' SO_3M and hydrogen;

M is selected from the group consisting of H, Li, Na, K and O.5 Ca;

R' is C_1-C_{10} alkyl; and

T is =N- or =C(Z)- wherein either:

(i) Z is selected from the group consisting of hydrogen, NH_2, OH, C_1-C_8 alkyl, C_3-C_7 cycloalkyl, aryl and C_1-C_6 perhaloalkyl, or

(ii) Z is a bridging moiety selected from the group consisting of -V-W- (wherein V is CH_2 or S and W is CH_2, O, S or NH) and -$(CH_2)_2$ -C(=Z)- wherein Z is O or H_2, the said bridging moiety being attached to the ortho position of ring b of the adjacent biphenyl group, thereby completing a ring.

78. (Allowed) A method according to claim 76, wherein the inhibitor is a compound of the formula (II):



(II)

wherein

R^1 is H, a halogen or OCF_3;

R^2 is H or C_1-C_6 alkyl;

R^3 is H or OR^6 wherein R^6 is H or C_1-C_6 alkyl;

R^4 is H or C_1-C_6 alkyl; or R^4 and R^3 form, together with phenyl ring b to which they are attached, a naphthalene ring; and

R^5 is cyclohexyl, phenoxy or benzoxy, or a phenyl ring which is unsubstituted or substituted by halogen; or R^4 and R^5 form, together with phenyl ring b to which they are attached, a phenanthrene ring.

79. (Allowed) A method according to claim 78, wherein the inhibitor is a compound of formula (IIb):



(IIb)

wherein M is H or Na.

80. (Allowed) A method according to claim 76, wherein the virus is a flavivirus selected from the group consisting of hepatitis viruses, yellow fever virus, West Nile virus, kunjin virus, dengue virus, St. Louis encephalitis virus, Japanese encephalitis virus, Murray valley encephalitis virus and tick-borne encephalitis virus.

81. (Currently Amended) A method according to claim ~~80~~ 76, wherein the virus is a rhabdovirus selected from vesicular stomatitis virus and rabies virus, or is the paramyxovirus RSV.

82. (Currently Amended) A method according to claim 76, wherein the method comprises administration of the inhibitor of formula (I) ~~medicament is for administration~~ with an interferon.

Claim 83 (Canceled).

84. (Previously Added) A method according to claim 82, wherein the interferon is a human interferon.

Claim 85 (Canceled).

86. (Previously Added) A method according to claim 82, wherein the interferon is selected from the group consisting of interferon α2, interferon α8, and interferon β.

Claim 87 (Canceled)

88. (Previously Added) A method according to claim 82, wherein the interferon is human interferon α8 having a specific activity of from $0.3x10^9$ to $3x10^9$ IU per mg protein.

Claim 89 (Canceled).

90. (Previously Added) A method according to claim 82, wherein the interferon is human interferon β having a specific activity of from $2x10^8$ to $8x10^8$ per mg protein.

Claim 91 (Canceled).

92. (Previously Added) A method according to claim 82, wherein the inhibitor and the interferon are used in respective amounts which produce a synergistic effect.

Claim 93 (Canceled).

94. (Currently Amended) A method according to claim 76, wherein the method further comprises administration of ~~medicament is for use with~~ an inhibitor of a second enzyme, which enzyme is selected from inosine monophosphate dehydrogenase, guanosine monophosphate synthetase, cytidine triphosphate synthetase and S-adenosylhomocysteine hydrolase.

Claim 95 (Canceled).

96. (Previously Added) A method according to claim 94, wherein the inhibitor of the second enzyme is mycophenolic acid, cyclopentenyl cytosine (CPE-C) or 3-deazaneplanocin A.

Claim 97 (Canceled).

98. (Previously Added) A method according to claim 94, wherein the inhibitor of the second enzyme and the inhibitor of dihydrooratate dehydrogenase are used in respective amounts which produce a synergistic effect.

Claim 99 (Canceled).

100. (Previously Added) A method according to claim 96, wherein the inhibitor of the second enzyme and the inhibitor of dihydrooratate dehydrogenase are used in respective amounts which produce a synergistic effect.

101. (Allowed) A compound of formula (IIa):



(IIa)

wherein

M is selected from the group consisting of H, Li, Na, K and 0.5 Ca;

R^{22} is H or C_1-C_6 alkyl;

R^{33} is H or OR^6 wherein R^6 is H or C_1-C_6 alkyl;

R^{44} is H or C_1-C_6 alkyl; and

R^{55} is phenyl, cyclohexyl, phenoxy or benzoxy;

or a metabolite or prodrug precursor thereof.

102. (Allowed) A compound according to claim 101, which is selected from:

2-(4-biphenylyl)-6-trifluoromethoxy-quinoline-4-carboxylic acid (compound I2K5);

2-(4-biphenylyl)-3-methyl-6-trifluoromethoxy-quinoline-4-carboxylic acid (compound I2K55);

2-(4-cyclohexylphenyl)-6-trifluoromethoxy-quinoline-4-carboxylic acid (compound I2K46);

2-(4-benzyloxy-2-methoxy-3-methyl-phenyl)-6-trifluoromethoxy-quinoline-4-carboxylic acid (compound I2K51); and

2-(4-phenoxyphenyl)-6-trifluoromethoxy-quinoline-4-carboxylic acid (compound I2K52).

103. (Allowed) A process for producing a compound of formula (IIa) as claimed

in claim 101, which process comprises

a) condensing a trifluoromethoxy-substituted isatin compound of the following formula (IX):



(IX)

with a ketone of formula (X):



(X)

in the presence of a base; and

(b) if desired, converting a resulting compound of formula (IIa) in which M is H into a pharmaceutically acceptable salt thereof wherein M is Li, Na, K or 0.5 Ca.

104. (Currently Amended) An anti-flavivirus, anti-rhabdovirus or anti-paramyxovirus agent comprising an inhibitor of dihydroorotate dehydrogenase which is a compound of formula (IIa):



(IIa)

---

wherein

M is selected from the group consisting of H, Li, Na, K and 0.5 Ca;

R^{22} is H or C_1-C_6 alkyl;

R^{33} is H or OR^6 wherein R^6 is H or C_1-C_6 alkyl;

R^{44} is H or C_1-C_6 alkyl; and

R^{55} is phenyl, cyclohexyl, phenoxy or benzoxy;

or a metabolite or prodrug precursor thereof.

~~formula (I) as defined in claim 76.~~

Claims 105-108 (Canceled).

109. (new) An anti-flavivirus, anti-rhabdovirus or anti-paramyxovirus agent according to claim 104, which further comprises an interferon.

110. (new) An anti-flavivirus, anti-rhabdovirus or anti-paramyxovirus agent according to claim 104, further comprising an inhibitor of a second enzyme, which enzyme is selected from inosine monophosphate dehydrogenase, guanosine

monophosphate synthetase, cytidine triphosphate synthetase and S-adenosylhomocystein hydrolase.

111. (new) An anti-flavivirus, anti-rhabdovirus or anti-paramyxovirus agent according to claim 110, which further comprises an interferon.